dedup-isc-ft-v107-score
float64 0.3
1
| uid
stringlengths 32
32
| text
stringlengths 1
17.9k
| paper_id
stringlengths 8
11
| original_image_filename
stringlengths 7
69
|
|---|---|---|---|---|
0.4561 | af52614baff44fd79168695f67335bcf | The chemical structure and reaction mechanism of 49 towards biothiols. | PMC10222014 | molecules-28-04252-sch023.jpg |
0.421118 | eed6cb1db6ea44208c1a5de1848df8b4 | Structure of probe 50 and its reaction mechanism towards biothiols and SO2. | PMC10222014 | molecules-28-04252-sch024.jpg |
0.426203 | 7a98c3b8361840f3b2b3f73c3f090d3d | Structure of probe 51 and its reaction mechanism towards thiols. | PMC10222014 | molecules-28-04252-sch025.jpg |
0.63949 | 97747f11bb4e4c61bbe44a1e76b96e4f | Storage stability test of TQ-loaded liposomes at +4 °C for 5 weeks. (A) LP-TQ1; (B) LP-TQ2 (mean ± SD, n = 3). | PMC10222138 | pharmaceutics-15-01516-g001.jpg |
0.594455 | f851dbe2b92a41c2bbf6c81bd9cde180 | Storage stability test of HA-coated liposomes at +4 °C for 5 weeks. (A) HA-LP-TQ1; (B) HA-LP-TQ2 (mean ± SD, n = 3). | PMC10222138 | pharmaceutics-15-01516-g002.jpg |
0.469597 | 5c601684a60d42a5ab705f5d0c41af04 | In vitro release profiles of TQ from the uncoated and HA-coated liposomes and TQ aqueous saturated solution in phosphate buffered saline (PBS) medium containing Tween 80 (0.5% w/v) at pH 7.4, at 37 °C. (Mean ± SD, n = 3). | PMC10222138 | pharmaceutics-15-01516-g003.jpg |
0.467473 | 94b1828788bd4d4cb338cb8c421307b9 | Antinociceptive properties of liposomes against carrageenan-induced mechanical hyperalgesia. Following intra-tendon injection of 20 µL of carrageenan 0.8% on day 1, the efficacy of peri-tendon injections (20 µL) of HA-LP-TQ1 (1 mg/mL), HA-LP-TQ2 (2 mg/mL), HA-LP, LP-TQ1 (2 mg/mL) and TQ (0.55 mg/mL) was evaluated. Formulations were injected on days 1, 3, 5, 7 and 10 and the response to a noxious mechanical stimulus was assessed by the paw pressure test in time course (days 1, 3, 5, 7, 10 and 13). Control animals were treated with vehicles. The value represents the mean of 8 rats performed in two different experimental sets. ** p < 0.01 compared to the vehicle + vehicle group; ^ p < 0.05 and ^^ p < 0.01 compared to the carrageenan + vehicle group. | PMC10222138 | pharmaceutics-15-01516-g004.jpg |
0.486746 | e72fa3100ba644d99cc0e9e341cf1fe7 | Antinociceptive properties of liposomes against carrageenan-induced spontaneous nociception. Following intra-tendon injection of 20 µL of carrageenan 0.8% on day 1, the efficacy of peri-tendon injections (20 µL) of HA-LP-TQ1 (1 mg/mL), HA-LP-TQ2 (2 mg/mL), HA-LP, LP-TQ1 (2 mg/mL) and TQ (0.55 mg/mL) was evaluated. Formulations were injected on days 1, 3, 5, 7 and 10 and the development of spontaneous nociception was assessed by the Incapacitance test in time course (days 1, 3, 5, 7, 10 and 13). Control animals were treated with vehicles. The value represents the mean of 8 rats performed in two different experimental sets. ** p < 0.01 compared to the vehicle + vehicle group; ^ p < 0.05 and ^^ p < 0.01 compared to the carrageenan + vehicle group. | PMC10222138 | pharmaceutics-15-01516-g005.jpg |
0.423791 | de1da89863ac4fd5b78b4aded5c234f5 | Antinociceptive properties of liposomes against carrageenan-induced motor alterations. Following intra-tendon injection of 20 µL of carrageenan 0.8% on day 1, the efficacy of peri-tendon injections (20 µL) of HA-LP-TQ1 (1 mg/mL), HA-LP-TQ2 (2 mg/mL), HA-LP, LP-TQ1 (2 mg/mL) and TQ (0.55 mg/mL) was evaluated. Formulations were injected on days 1, 3, 5, 7 and 10 and the efficacy against motor alterations was assessed by the beam balance test in time course (days 1, 3, 5, 7, 10 and 13). Control animals were treated with vehicles. The value represents the mean of 8 rats performed in two different experimental sets. ** p < 0.01 compared to the vehicle + vehicle group; ^^ p < 0.01 compared to the carrageenan + vehicle group. | PMC10222138 | pharmaceutics-15-01516-g006.jpg |
0.429438 | f5a51362e0774219b69c0a015b2012a7 | Antinociceptive properties of liposomes against carrageenan-induced motor alterations. Following intra-tendon injection of 20 µL of carrageenan 0.8% on day 1, the efficacy of peri-tendon injections (20 µL) of HA-LP-TQ1 (1 mg/mL), HA-LP-TQ2 (2 mg/mL), HA-LP, LP-TQ1 (2 mg/mL) and TQ (0.55 mg/mL) was evaluated. Formulations were injected on days 1, 3, 5, 7 and 10 and the efficacy against motor alterations was assessed by the Rota rod test in time course (days 1, 3, 5, 7, 10 and 13). Control animals were treated with vehicles. The value represents the mean of 8 rats performed in two different experimental sets. ** p < 0.01 compared to the vehicle + vehicle group; ^ p < 0.05 and ^^ p < 0.01 compared to the carrageenan + vehicle group. | PMC10222138 | pharmaceutics-15-01516-g007.jpg |
0.383859 | ebad56a882c844b9874ba632b43cacc5 | Histological evaluation of HA-LP-TQ2 injections on tendinopathy models. After 5 peri-tendon treatments with HA-LP-TQ2 on carrageenan, damaged tendon samples of the animals were collected. To make histological evaluation, Hematoxylin-Eosin was performed. The histological score was calculated according to the following parameters: extracellular matrix organization (0–2), tissue homogeneity (0–2), presence of degenerative changes (0–2), cell nucleus morphology (0–2), cell distribution (0–2) and alignment (0–2), vascularization (0–1), inflammation (0–1) and Azan-Mallory red stain intensity (0–2). Total score for each animal ranged between 0 (most severe tendon impairment) and 16 points (control, normal tendon). ** p < 0.01 compared to the vehicle + vehicle group; ^^ p < 0.01 compared to the carrageenan + vehicle group. | PMC10222138 | pharmaceutics-15-01516-g008.jpg |
0.441942 | 2544b79f650a4b01976d328937491374 | PRISMA 2020 flow diagram. | PMC10222379 | life-13-01193-g001.jpg |
0.442019 | e1e1c4b226764afd8ab40dbe2cc410d9 | Risk of bias graph and summary [4,30,31,32,33,34,35,36,39]. | PMC10222379 | life-13-01193-g002.jpg |
0.453402 | 79059d7376594cbeb3ff69753637af80 | Effectiveness of resistance training on static balance [30,31,32]. | PMC10222379 | life-13-01193-g003.jpg |
0.401082 | 90ceddd3219247129b06be4bcb331070 | Effectiveness of balance training on static balance [31,33,34]. | PMC10222379 | life-13-01193-g004.jpg |
0.469373 | 6ca78cd6e84f448a846730ba00fcd9e0 | Effectiveness of multicomponent training on static balance [4,35]. | PMC10222379 | life-13-01193-g005.jpg |
0.44195 | dc99805169724efab9065712fef07bbb | Main phenolic compounds present in A. satureioides: (a) quercetin, (b) 3-O-methylquercetin, (c) luteolin. | PMC10222649 | plants-12-02027-g001.jpg |
0.441871 | 708838267b8d43f59a8f7ec56ba4a64b | GC–MS chromatogram of A. satureioides extract (5 mg). | PMC10222649 | plants-12-02027-g002.jpg |
0.50588 | 154c1da1a12c4a5db112982399fe212e | MTT assay of HaCaT cells: the control value represents mean ± SD for triplicate tests of the growth control with no extract. Results are expressed as the percentage of the control. | PMC10222649 | plants-12-02027-g003.jpg |
0.435898 | c91ff55a9c3647a3a44ea318ea1ad6a2 | MIC and MBC concentrations of the hydroalcoholic extract. | PMC10222649 | plants-12-02027-g004.jpg |
0.406251 | c2e5b3b7c0484706a5ea8ee8697089a0 | Inhibition zones of the extract on agar plates. | PMC10222649 | plants-12-02027-g005.jpg |
0.458546 | 7e384b64ccd24c7698d74be8c84f53ab | Inhibition zones of Emulsions 1 and 2 with 0%, 1% and 2% (w/w) of the extract. | PMC10222649 | plants-12-02027-g006.jpg |
0.416304 | 43081cd4591a4ceaa4133d27c089e3b0 | The development of a GPCR-directed theranostic peptide radioligand from bench to patient. The peptide conjugate is synthesized and radiolabeled and its biological profile evaluated first in cells and tumor-bearing mice expressing the target. Best candidates are selected for translation in humans. Labeling with a gamma emitter allows for SPECT imaging whereas a positron emitter enables PET imaging. Both techniques will indicate patients eligible for radiotherapy with an alpha, beta or Auger electron emitter to eradicate tumor cells, according to precision medicine principles. | PMC10222684 | pharmaceuticals-16-00674-g001.jpg |
0.493563 | 19f6d12172154410820172c41981e3dd | Chemical structures of (a) SS-28: H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Leu-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys]-OH, and SS-14: H-Ala-Gly-c[Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys]-OH, (b) OctreoScan®: [111In]In-DTPA-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr(ol), and (c) [68Ga]Ga/[177Lu]Lu-DOTA-TATE: [68Ga]Ga/[177Lu]Lu-DOTA-DPhe-c[Cys-Phe-DTrp-Lys-Thr-Cys]-Thr-OH. | PMC10222684 | pharmaceuticals-16-00674-g002a.jpg |
0.399006 | 8d6a42d5cfd846cc8f60ee04fca58b04 | Chemical structures of (a) DOTA-BASS: DOTA-pNO2-Phe-c[DCys-Tyr-DTrp-Lys-Thr-Cys]-DTyr-NH2, (b) [177Lu]Lu-DOTA-JR11, or [177Lu]Lu-OPS201: DOTA-pCl-Phe-c[DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys]-DTyr-NH2, (c) [68Ga]Ga-NODAGA-JR11, or [68Ga]Ga-OPS202, and (d) [177Lu]Lu-DOTA-LM3: [177Lu]Lu-DOTA-pCl-Phe-c[DCys-Tyr-DAph(Cbm)-Lys-Thr-Cys]-DTyr-NH2. | PMC10222684 | pharmaceuticals-16-00674-g003.jpg |
0.39835 | 7219376bcfbc4dfaa86bd21623d8fa24 | A patient with well-differentiated, non-functioning metastatic pancreatic NEN. [68Ga]Ga-DOTA-TATE PET/CT showed lesions in liver and lymph nodes with extremely low uptake (leftmost image), not exhibiting significant glucose hypermetabolism (second image from left). [68Ga]Ga-NODAGA-LM3 PET/CT instead showed disseminated metastases, with intense uptake in liver and lymph nodes (third image from left). After four cycles of [177Lu]Lu-DOTA-LM3 PRRT, restaging [68Ga]Ga-NODAGA-LM3 PET/CT showed excellent response (partial remission, rightmost image).This research was originally published in JNM 2020 ([64]; https://jnm.snmjournals.org/content/jnumed/62/11/1571/F6.large.jpg). | PMC10222684 | pharmaceuticals-16-00674-g004.jpg |
0.496735 | ca910d7316324280adb612e92b0a0796 | Amino acid sequences of frog BBN, mammalian NMB, GRP and NMC, with conserved residues highlighted in bold; each peptide preferably binds to the receptor subtype(s) indicated by the arrow(s) on the right-hand side of the diagram. | PMC10222684 | pharmaceuticals-16-00674-g005.jpg |
0.403661 | b454b186ca444aa79a40e426f0d1b34b | Chemical structures of (a) [99mTc]Tc-RP527: [99mTc]Tc-N3S-Gly-5Ava-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, (b) [99mTc]Tc-DB4: [99mTc]Tc-N4-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Nle-NH2, and (c) [68Ga]Ga/[177Lu]Lu-AMBA: [68Ga]Ga/[177Lu]Lu-DOTA-Gly-4-aminobenzoyl-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, showing the metal chelate, linker and amino acid sequence; 5aVa: 5-aminovaleric acid. | PMC10222684 | pharmaceuticals-16-00674-g006.jpg |
0.399691 | fb4658599b564df59126ee7bd2222f4c | Chemical structures of (a) [99mTc]Tc-DB15: [99mTc]Tc-N4-AMA-DGA-[DPhe6,Sar11,Leu13-NHEt]BBN(6-13), (b) [68Ga]Ga-SB3: [68Ga]Ga-DOTA-AMA-DGA-[Dphe6,Leu13-NHEt]-BBN(6-13), (c) [68Ga]Ga/[177Lu]Lu-RM2: [68Ga]Ga/[177Lu]Lu-DOTA-Pip-[Dphe6,Sta13,Leu14-NH2]BBN(6-14), and (d) [68Ga]Ga/[177Lu]Lu-NeoBOMB1: [68Ga]Ga/[177Lu]Lu-DOTA-AMA-DGA-[Dphe6,His12-NHCH(CH2-CH(CH3)2)2]BBN(6-12), showing the metal chelate, linker and amino acid sequence. | PMC10222684 | pharmaceuticals-16-00674-g007.jpg |
0.527744 | 4c07d7169c2e445ca46f4e12dd7380ad | [68Ga]Ga-NeoBOMB1 PET/CT in (a) in a prostate adenocarcinoma patient, postradical prostatovesiculectomy with pelvic lymphadenectomy, intensity-modulated radiotherapy, and androgen-deprivation therapy: PET MIP (A), serial PET transverse (B), corresponding CT transverse (C), and fusion PET/CT (D) images. Multiple mediastinal, abdominal, paraesophageal, and pelvic lymph node metastases are indicated by arrows and crossbars.—This research was originally published in JNM 2017 (Ref. [114]; https://jnm.snmjournals.org/content/jnumed/58/1/75/F6.large.jpg). (b) a patient with GIST of ileum and histologically verified liver metastases (left: PET MIP, right: transverse fusion PET/CT)—This research was originally published in JNM 2020 ([117]; https://jnm.snmjournals.org/content/jnumed/61/12/1749/F4.large.jpg). | PMC10222684 | pharmaceuticals-16-00674-g008.jpg |
0.397045 | 1a9df78c00eb4a7f9ecfd51b091731d8 | Chemical structures of (a) [99mTc]Tc-DG2: [99mTc]Tc-N4-Gly-DGlu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2, (b) [111In]In-DOTA-MG0: [111In]In-DOTA-Dglu-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2, (c) [111In]In-DOTA-MG11: [111In]In-DOTA-Dglu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2, and (d) [111In]In-CP04 (Xaa: Met)/[111In]In-PP-F11N (Xaa: Nle): [111In]In-DOTA-Dglu-(Dglu)5-Ala-Tyr-Gly-Trp-Xaa-Asp-Phe-NH2. | PMC10222684 | pharmaceuticals-16-00674-g009.jpg |
0.48725 | 6b9781c879db4f809000659dcdba9a27 | (a) Chemical structure of [68Ga]Ga-MGS5: [68Ga]Ga DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-NH2, (b) MIP (A) and axial fused PET/CT with [68Ga]Ga-MGS5 at 1 h pi in a metastatic MTC patient with local recurrence on the right paratracheal region (B) white arrow, left cervical lymph node metastasis (C) red arrow, multiple hepatic metastases (D) yellow arrows, and metastases in the left iliac bone and left femur (E) orange arrows. This research was originally published in JNM 2023 ([151]; https://jnm.snmjournals.org/content/early/2023/01/19/jnumed.122.264977). | PMC10222684 | pharmaceuticals-16-00674-g010.jpg |
0.446723 | 656b59b4eb834ebb84b914c315a62fc6 | Chemical structures of Z360 (nastorazepide) analogs with different chelators coupled to its free carboxy group via a linker for labeling with theranostic radiometals, such as Tc-99m, Ga-67/68, In-111 and Lu-177 and showing antagonistic properties at the CCK2R. | PMC10222684 | pharmaceuticals-16-00674-g011.jpg |
0.444757 | 7992b53b30fe4deab305a74dd62d917f | A schematic Jablonski diagram showing targeted photodynamic therapy (tPDT). The method is based on a photosensitizer (PS) attached to a molecule selective for a certain target. The PS is activated by light of a specific wavelength (preferably in the near infrared range, NIR) to a higher-energy state, upon which energy is transferred from the activated PS to surrounding oxygen to form reactive oxygen species (ROS). These can induce irreversible damage to a cell directly or to the tumor-associated vasculature, leading to cell death. | PMC10222684 | pharmaceuticals-16-00674-g012.jpg |
0.443346 | 5771c37b87a34597b429fe174078891f | 3D Chromatogram of jengkol extract using HPLC-PDA. | PMC10222784 | molecules-28-03984-g001.jpg |
0.507457 | 037db83a7b684621b7af84c836640ebb | HPLC Chromatogram at 210 nm. (a) Fraction (A) of jengkol extract (10–20) and (b) fraction (B) of jengkol extract (20–30). | PMC10222784 | molecules-28-03984-g002.jpg |
0.508294 | 6cc70e72c265479993a7edfaa671c431 | LC chromatogram for (a) fraction (A) of the jengkol extract, (b) fraction (B1) of the jengkol extract, and (c) fraction (B2) of the jengkol extract. | PMC10222784 | molecules-28-03984-g003.jpg |
0.450098 | 66e25e3d6a0f49a88bcffdc131d57cf3 | Mass spectrum fraction of the jengkol extract (A), i.e., (a) selenomethionine (m/z 198), (b) gamma-glu-MetSeCys (m/z 313), and (c) the Se-S conjugate of cysteine-selenoglutathione (m/z 475). | PMC10222784 | molecules-28-03984-g004.jpg |
0.457189 | 0e6c488c138a4b15b2869497e69d1de2 | Molecular docking visualization of PPAR-γ and organic Se (a) the Se-S conjugate of cysteine-selenoglutathione (Se03), (b) selenomethionine (Se01) and (c) gamma-GluMetSeCys (Se02). | PMC10222784 | molecules-28-03984-g005.jpg |
0.433867 | 61aa4dd6bad64b469ab92a9d67326f57 | Molecular docking visualization of AKT/PI3K and (a) Native Ligand, (b) selenomethionine (Se01) and (c) Gamma-GluMetSeCys. | PMC10222784 | molecules-28-03984-g006.jpg |
0.499178 | ac0e0e008445437493ff8ad12ec5de8c | Molecular docking visualization of NF-ΚB and (a) Native Ligand, (b) selenomethionine (Se01) and c) gamma-GluMetSeCys (Se02). | PMC10222784 | molecules-28-03984-g007.jpg |
0.442152 | 39ff01547a1a465985b6c0ee5c002cbd | (a) RMSD complex of PPAR-γ; (b) RMSF value of native ligand–PPAR-γ (orange) and gamma-GluMetSeCys (Se02)–PPAR-γ (yellow) complexes; (c) RMSD complex of PI3K; (d) RMSF value of native ligand–PI3K (orange) and gamma-GluMetSeCys (Se02)–PI3K (yellow) complexes; (e) RMSD complex of NF-ΚB; (f) RMSF value of native ligand–NF-ΚB (orange) and Se-S conjugate of cysteine-selenoglutathione (Se03)– NF-ΚB (yellow) complexes. | PMC10222784 | molecules-28-03984-g008.jpg |
0.450577 | b5426457ad984c62b6f698d64a5e14f2 | (a) SASA plot of the native ligand–PPAR-γ (orange) and gamma-GluMetSeCys (Se02)–PPAR-γ (yellow) complexes; (b) SASA plot of the native ligand–PI3K (orange) and gamma-GluMetSeCys (Se02)–PI3K (yellow) complexes; (c) SASA plot of the native ligand–NFκB (orange) and the Se-S conjugate of cysteine-selenoglutathione (Se03)–NF-KB (yellow) complexes. | PMC10222784 | molecules-28-03984-g009.jpg |
0.417132 | d39b6f52dd01455a8c20af2493580aa1 | (a) Rg plot of the native ligand–PPAR-γ (orange) and gamma-GluMetSeCys (Se02)–PPAR-γ (yellow) complexes; (b) Rg plot of the native ligand–PI3K (orange) and gamma-GluMetSeCys (Se02)–PI3K (yellow) complexes; (c) Rg plot of the native ligand–NF-ΚB (orange) and the Se-S conjugate of cysteine-selenoglutathione (Se03)–PI3K (yellow) complexes. | PMC10222784 | molecules-28-03984-g010.jpg |
0.511509 | d9ad0727a78b4bb1b307676b712056cc | Locations of sampling sites at the coking wastewater treatment plant, Taiyuan, China. | PMC10223012 | toxics-11-00415-g001.jpg |
0.468063 | 14dbac495b7d4daa8e85e34a4e316147 | Relative abundance of PAHs in soils in the study area. | PMC10223012 | toxics-11-00415-g002.jpg |
0.416803 | 86fc568f99ce4379ad0bc52ec67ea31d | Composition ratios of PAHs in soil samples. | PMC10223012 | toxics-11-00415-g003a.jpg |
0.504317 | e88a9ec1f2864219b219afbc00b1f6ef | Nemerow synthesis index (PN) of PAHs in soil samples. | PMC10223012 | toxics-11-00415-g004.jpg |
0.492816 | 7e19d64586a34b3aad17d1a2f6ab8c40 | Contributions of different exposure pathways for children, adolescents, and adults, as calculated by ILCR method. | PMC10223012 | toxics-11-00415-g005.jpg |
0.649407 | 44fbbd78f51c4fb08221e66cfe6290a9 | Chemical structure of a chalcone. | PMC10223217 | molecules-28-04009-g001.jpg |
0.629231 | 825beda0e9994be38f10ff3173cd1701 | Chemical structure of benzocoumarin-chalcones. | PMC10223217 | molecules-28-04009-g002.jpg |
0.595854 | bcbe830fc6a34176aac0e2e5f78acfb3 | Chemical structure of chalcones, MIPP and MOMIPP. | PMC10223217 | molecules-28-04009-g003.jpg |
0.580367 | 3331b8349fb340fbbccf3b7a88abae56 | Chemical structure of TNF-α inhibitor compounds. | PMC10223217 | molecules-28-04009-g004.jpg |
0.449797 | 6bdc9788a74240caa94858708f41d703 | Chemical structure of colon cancer inhibitor compounds. | PMC10223217 | molecules-28-04009-g005.jpg |
0.480892 | 57292b2c712245e3ac038a14c323ad57 | Chemical structure of lung cancer inhibitor compounds. | PMC10223217 | molecules-28-04009-g006.jpg |
0.424705 | f65904c41a2746e7857233449dfba616 | Chemical structure of breast cancer inhibitor compounds. | PMC10223217 | molecules-28-04009-g007.jpg |
0.476638 | 9c06aac867e14602bf0f82754ab81e0b | Chemical structure of oral cancer inhibitor compounds. | PMC10223217 | molecules-28-04009-g008.jpg |
0.421321 | ce62b349af68415bbcb36d35c1924708 | Chemical structure of leukemia inhibitor compounds. | PMC10223217 | molecules-28-04009-g009.jpg |
0.413425 | a87e0ce03fb14163a084d2d2e3d473f6 | Chemical structure of hepatocarcinoma inhibitor compounds. | PMC10223217 | molecules-28-04009-g010.jpg |
0.622692 | 5db4b08ade914a77927e83cd019eb4b8 | Chemical structure of cervical cancer inhibitor compounds. | PMC10223217 | molecules-28-04009-g011.jpg |
0.604995 | a3e71e2714484bb6ac4649b695db4d98 | Chemical structure of glioblastoma inhibitor compounds. | PMC10223217 | molecules-28-04009-g012.jpg |
0.603529 | 5fc30d2d4b3b42fa999dc6c3c2bab2b3 | Chemical structure of melanoma inhibitor compounds. | PMC10223217 | molecules-28-04009-g013.jpg |
0.492648 | dad905a229324205ba2d6ba4df5ae306 | Chemical structure of the series of compounds submitted to PLS analysis. (A) Active compounds; (B) inactive compounds. | PMC10223217 | molecules-28-04009-g014a.jpg |
0.423789 | 87378825cf01429d92dd72d9d2f329cc | Arrangement of objects in relation to the activity of compounds. | PMC10223217 | molecules-28-04009-g015.jpg |
0.428911 | d6ef80e6ad9c46e5a34e17e53153ee0d | Coefficient graph generated from the PLS model. | PMC10223217 | molecules-28-04009-g016.jpg |
0.401801 | 136a31901bbf49e6a14bf918aeae047e | The synergy of ECG recording wearable devices and artificial intelligence algorithms enables disease detection and prediction. | PMC10223364 | sensors-23-04805-g001.jpg |
0.426634 | ec174f47075d4823bf8bf7e556eb9e52 | Main areas of electrocardiography- and artificial-intelligence-based medical application reviewed in the present work. | PMC10223364 | sensors-23-04805-g002.jpg |
0.525986 | d4679146b3fd45f98d2997687e3ed1e5 | Components of a normal electrocardiogram include P- and T-waves and the QRS complex. | PMC10223364 | sensors-23-04805-g003.jpg |
0.452092 | 41e1df64bb604de88253e2a56a803d48 | Sleep apnea and its consequences relative to diagnostics potentially enabled by continuous real-time ECG monitoring. | PMC10223364 | sensors-23-04805-g004.jpg |
0.459022 | b3bbf2d3638b47d59e3ca9a92f5fb1ea | Stress response and its physiology relative to diagnostics potentially enabled by continuous, real-time ECG monitoring. | PMC10223364 | sensors-23-04805-g005.jpg |
0.409516 | 31b4787064f34eabb49f8ead6ce8479d | Preparation process of core–shell structure zinc oxide. | PMC10223490 | polymers-15-02353-g001.jpg |
0.471604 | 6b58fa2df5144f0dbbe6a073e00ed869 | XRD of zinc oxide with core–shell structure of different nuclear materials. | PMC10223490 | polymers-15-02353-g002.jpg |
0.526031 | ab5d8e0ef19a4003add672fea8551da7 | SEM image of the core–shell structure zinc oxide: (a) CaCO3; (b) BaSO4; (c) SiO2; (d) CBp; (e) GO. | PMC10223490 | polymers-15-02353-g003.jpg |
0.445349 | 3c706f37d35e42e0a8d77d7bb0391022 | TEM image of the core–shell structure zinc oxide: (a) CaCO3; (b) BaSO4; (c) SiO2; (d) CBp; (e) graphene. | PMC10223490 | polymers-15-02353-g004.jpg |
0.456345 | 531e51903aa041e59509e2a70759f260 | Mechanical properties of zinc oxide with core–shell structure. (a) Stress-strain curve; (b) tensile strength, elongation at break; (c) tear strength; (d) wear resistance. | PMC10223490 | polymers-15-02353-g005.jpg |
0.450115 | 5fcde03891c04cdfbf48bbaf8794dc14 | DMA of core–shell ZnO with different core materials. (a) tanδ; (b) storage modulus. | PMC10223490 | polymers-15-02353-g006.jpg |
0.378881 | c1d2ab6818e7465a87089bfc4b779b26 | Effect of core–shell zinc oxide with different core materials on the aging performance of tire tread rubber. (a) Tensile strength after aging; (b) tear strength after aging. | PMC10223490 | polymers-15-02353-g007.jpg |
0.471511 | cf6c10b9d6a74bc1b7bdeb0328055921 | The PRISMA flow chart. | PMC10223551 | life-13-01125-g001.jpg |
0.407652 | 4ae0b9692a8545158e5a978e6e8e1c6d | Lipogenic tumour component comprising atypical lipoblasts encompassed by a lightly basophilic matrix with myxoid aspect. H.E., ob. 200×. | PMC10224154 | medicina-59-00967-g001.jpg |
0.585994 | ef10ef992f7c41a1a25f69fca1b3765b | The tumour proliferation with adipocytic differentiation displays round and spindle neoplastic cells with hyperchromatic nuclei. H.E., ob. 400×. | PMC10224154 | medicina-59-00967-g002.jpg |
0.476763 | a30c8487fa21423183faffd293d4cb4e | Malignant tumour proliferation with adipocytic differentiation exhibiting abrupt transition towards a non-lipogenic area, containing atypical spindle cells with fasciculate arrangement. H.E., ob. 100×. | PMC10224154 | medicina-59-00967-g003.jpg |
0.569507 | 848b9fea69424d22821909ce08c7bd92 | Dedifferentiated tumour area composed of spindle cells with hyperchromatic, moderately pleomorphic nuclei, showing no lipogenic areas and inapparent lipoblasts. H.E., ob. 200×. | PMC10224154 | medicina-59-00967-g004.jpg |
0.455671 | 7e34e5fa6b7b40c9aca7fc59a2be0e4f | Dedifferentiated tumour component exhibiting intersecting fascicles of malignant spindle cells with no lipogenic areas. H.E., ob. 200×. | PMC10224154 | medicina-59-00967-g005.jpg |
0.558931 | 278b5a5638c44f0b9b00f7e28d544075 | The non-lipogenic tumour component displays spindle cells with hyperchromatic nuclei; some of them with conspicuous nucleoli, as well as mitotic figures. HE, ob. 400×. | PMC10224154 | medicina-59-00967-g006.jpg |
0.423188 | 9143cd64491943fc9ee69bbe539679cc | (A) S100 expression within the malignant cells of the lipogenic tumour area with myxoid stroma. S100, ob. 200×. (B) S100 expression within the malignant cells of the dedifferentiated tumour component. S100, ob. 200×. | PMC10224154 | medicina-59-00967-g007.jpg |
0.447459 | d2a8381a57db4908ba6db2d7b5e6a9e2 | (A) Strong, diffuse p16 expression within the malignant cells of the lipogenic tumour area. p16, ob. 200×. (B) Strong, diffuse p16 expression within the malignant cells of the non-lipogenic tumour area. p16, ob. 200×. | PMC10224154 | medicina-59-00967-g008.jpg |
0.484666 | 5c76e8942617448aa81c01a4289d85ec | (A) CD34 staining highlighting the prominent “chicken-wire” capillary network within the lipogenic tumour area. HE, ob. 200×. (B) Tumour cells within the dedifferentiated tumour component are negative for CD 34. Immunohistochemical staining also demonstrates a delicate arborizing vasculature present within the outer limits of the proliferation. CD 34, ob. 100×. | PMC10224154 | medicina-59-00967-g009.jpg |
0.413325 | e2fd52a991014202aa15998b1cac15bc | (A) The Ki 67 proliferation marker is expressed within around 10% of the malignant cells from the lipogenic area with myxoid stroma. Ki 67, ob. 200×. (B) The Ki 67 proliferation marker is expressed within 10% of the malignant spindle cells from the dedifferentiated tumour area. Ki 67, ob. 200×. | PMC10224154 | medicina-59-00967-g010.jpg |
0.441584 | d47d7f3800fe46bd9f7b4d78b8ecc408 | Strong MDM2 expression within the malignant cells of the non-lipogenic tumour area. MDM2, ob. 200×. | PMC10224154 | medicina-59-00967-g011.jpg |
0.540105 | b9827aa0a47e438b8b0da495bb6913e6 | Strong CDK4 expression within the malignant cells of the non-lipogenic tumour area. CDK4, ob. 200×. | PMC10224154 | medicina-59-00967-g012.jpg |
0.40602 | b6c345a221a34b5896e09f66a341b0dc | Schematic of the experimental design of the prospective cohort study of Borrelia IgG seroprevalence in forestry workers over 8 years. | PMC10224454 | life-13-01143-g001.jpg |
0.486131 | 1f1a790a89a2466482c733c26ecf9cb9 | The region in the Netherlands where the forestry workers were employed is circled. Dark red regions are known for their higher incidence of Borrelia infection. The ranges refer to the number of diagnoses of erythema migrans per 100,000 inhabitants per year. | PMC10224454 | life-13-01143-g002.jpg |
0.429224 | 7e96aa0ed7d7483f9a6b4455868d1b80 | IgG seropositivity by year in relation to the number of tick bites (* = p < 0.05). | PMC10224454 | life-13-01143-g003.jpg |
0.514138 | 16078862d1eb40ee89d20e660c558329 | Cumulative survival model (Kaplan–Meier) of time to IgG seroconversion in relation to tick bites. | PMC10224454 | life-13-01143-g004.jpg |
0.413509 | dd50d85115994d5c86d0ea1ae259903c | Clustered error bars (95% CI) of mean Borrelia burgdorferi 1 × 106 pg/mL 24 h IL-1b PBMC by year and number of tick bites. 1.000 represents 1000 pg/mL. | PMC10224454 | life-13-01143-g005.jpg |
0.461163 | f0bb634cb6d84192a3920a5530686b25 | Structure and electrical characteristics of the multi-terminal floating-gate memristor (MT-FGMEM).a, b Schematic and optical images of the MT-FGMEM comprises monolayer MoS2/h-BN/graphene heterostructures as a semiconducting channel, a tunneling insulator, and a floating gate, respectively. Multiple electrodes V1, V2, V3, V4, and V5 are located on MoS2. VFG is connected to graphene to measure the FG potential. Scale bar is 10 µm. c Cross-sectional schematics, and operation principle of MT-FGMEM. d Electrical behaviors of V4-V5 channel before (dashed line) and after charging shared graphene floating gate by V1 (black line), V2 (red line) and V3 (blue line). | PMC10224934 | 41467_2023_38667_Fig1_HTML.jpg |
0.440012 | b0acf71692dd4bb29adfbaa1a515c0bb | Spike-based multilevel memory behavior of MT-FGMEM.a Schematics of operation of spike-based multilevel memory in MT-FGMEM. (i) Full erasing by continuous negative bias on V1, (ii–iv) programming by positive-spike voltage on V2. Energy band diagram of the MoS2 channel between V2-S. b Typical electrical multilevel behavior of MT-FGMEM under the sequential spikes. Spikes (6 V, 0.1 s) are applied between V2-S electrodes (top panel-navy line), and FG potential (VFG, middle panel-olive line) and MoS2 channel current (Ids, bottom panel-orange line) are measured simultaneously. c Spike amplitude (Va) dependency on multilevel behavior. d Spike duration (tW) dependency on multilevel behavior. e Retention of multilevel in MT-FGMEM. f, g Multilevel potentiation, and depression of MT-FGMEM under 50 sequential spikes. h Representative current at each of the 50 levels in f and g. i Transfer characteristics of same device under gate voltage application on graphene. The dashed line indicates the theoretical simulation of the triode region in FET. | PMC10224934 | 41467_2023_38667_Fig2_HTML.jpg |
0.430886 | 5939b661e324428f8248475c24565586 | Imitation of multiple connections in biological neurons by configuration of multi-terminal FG and comparator.a Illustration of five connections in biological neurons. Pre-spikes of pre-neurons (V1, V2, V3, and V4) are integrated at the membrane potential of post-neuron (VFG), and then generate post-spikes (Vp). b Membrane potential for typical neuronal spike process. c Schematics of ion movement through the membrane gates at (i) EPSP, (ii) IPSP, (iii) depolarization, and (iv) repolarization. d Schematics of five connections in artificial neurons formed of multi-terminal FG and comparator configuration. Pre-spikes (V1, V2, V3, and V4) are integrated at the FG potential (VFG), and then generate post-spike (Vp). e FG potential for neuronal spike process. f Schematics of FG charging and discharging at (i) EPSP, (ii) IPSP, (iii) depolarization, and (iv) repolarization. g Retention behavior of 7 nm h-BN (left panel) and 4 nm h-BN (right panel). h Schematics of temporal summation in biological neurons. i Temporal summation LIF process of MT-FGMEM and comparator configuration. j Schematics of spatial summation in biological neurons. k Spatial summation LIF process of MT-FGMEM and comparator configuration. | PMC10224934 | 41467_2023_38667_Fig3_HTML.jpg |
0.435949 | 5f7de171b4ec462d83b51f7d560e3f1a | Unsupervised learning in artificial neuron and synapse based on MT-FGMEM.a Schematics of basic synapse-neuron assembly for unsupervised learning process by synaptic STDP and neuronal LIF functions. b, c STDP by correlation between pre-spike and post-spike. Only potentiation is used for our unsupervised learning simulation. d STDP based spike current change along the time difference between pre-spike and post-spike. e The unsupervised STDP weight change along the epoch (post-spike generation) in synapse (MT-FGMEM) and neuron (FG-com) unit cell. With (Δt ~ 0 s) or without feedback (Δt ~ \documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{upgreek}
\setlength{\oddsidemargin}{-69pt}
\begin{document}$${{{{{\rm{\infty }}}}}}$$\end{document}∞) of post-spike is controlled by connect and disconnect of feedback line, respectively. | PMC10224934 | 41467_2023_38667_Fig4_HTML.jpg |
0.411205 | f16aec1ca065490caf0583c07d6f9d1c | Single-layer spiking neurosynaptic network.a, b Optical images of neurosynaptic array with neuron-FG and synapse. c Monitoring the responses of orientation-selective neurons in visual cortex V1 to various directional stimuli. d 3 × 3 binary input images that represent the directions |, –, \ and circuit schematic of 3 output neurons, each with 9 synapses. e–g Real-time synaptic weight changes under 40 sequential input spikes (epoch). h–j Pattern classification by evolution of synapse conductance along the training epoch. | PMC10224934 | 41467_2023_38667_Fig5_HTML.jpg |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.